Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab and Cadonilimab plus Chemotherapy in ES-SCLC
NCT06769971Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab in small cell lung cancer (SCLC), sponsored by Sichuan University. Started Feb 2025; status: recruiting.
02
Drugs
ivonescimabcadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06769971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769971.